{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T11:24:00Z","timestamp":1743161040365,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10072-021-05567-7","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T23:04:37Z","timestamp":1629846277000},"page":"4881-4884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-8406","authenticated-orcid":false,"given":"Lorenzo","family":"Saraceno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela Laura","family":"Susani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Raffaella","family":"Marazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Moioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio Clemente","family":"Agostoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Protti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"issue":"10229","key":"5567_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054\u20131062. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"5567_CR2","doi-asserted-by":"publisher","first-page":"102073","DOI":"10.1016\/j.msard.2020.102073","volume":"39","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Hawkes C, Lechner-Scott J et al (2020) The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 39:102073. https:\/\/doi.org\/10.1016\/j.msard.2020.102073","journal-title":"Mult Scler Relat Disord"},{"key":"5567_CR3","doi-asserted-by":"publisher","first-page":"102402","DOI":"10.1016\/j.msard.2020.102402","volume":"45","author":"E Fern\u00e1ndez-D\u00edaz","year":"2020","unstructured":"Fern\u00e1ndez-D\u00edaz E, Gracia-Gil J, Garc\u00eda-Garc\u00eda JG et al (2020) COVID-19 and multiple sclerosis: a description of two cases on alemtuzumab. Mult Scler Relat Disord 45:102402. https:\/\/doi.org\/10.1016\/j.msard.2020.102402","journal-title":"Mult Scler Relat Disord"},{"key":"5567_CR4","doi-asserted-by":"publisher","unstructured":"Carandini T, Pietroboni AM, Sacchi et al (2020) Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: a mild uncomplicated infection despite intense immunosuppression. Mult Scler:1352458520926459. https:\/\/doi.org\/10.1177\/1352458520926459","DOI":"10.1177\/1352458520926459"},{"key":"5567_CR5","doi-asserted-by":"publisher","first-page":"102314","DOI":"10.1016\/j.msard.2020.102314","volume":"44","author":"C Guevara","year":"2020","unstructured":"Guevara C, Villa E, Cifuentes M, Naves R, Grazia J (2020) Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab. Mult Scler Relat 44:102314. https:\/\/doi.org\/10.1016\/j.msard.2020.102314","journal-title":"Mult Scler Relat"},{"key":"5567_CR6","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.msard.2020.102447","volume":"46","author":"C Fiorella","year":"2020","unstructured":"Fiorella C, Lorna G et al (2020) COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: insight to the immune response after COVID. Multiple Sclerosis and Related Disorders 46:102447. https:\/\/doi.org\/10.1016\/j.msard.2020.102447","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"5567_CR7","doi-asserted-by":"publisher","first-page":"102297","DOI":"10.1016\/j.msard.2020.102297","volume":"44","author":"J Mat\u00edas-Guiu","year":"2020","unstructured":"Mat\u00edas-Guiu J, Montero-Escribano P, Pytel V, Porta-Etessam J, Matias-Guiu JA (2020) Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Mult Scler Related Disorders 44:102297. https:\/\/doi.org\/10.1016\/j.msard.2020.102297","journal-title":"Mult Scler Related Disorders"},{"key":"5567_CR8","doi-asserted-by":"publisher","unstructured":"Sormani MP, De Rossi N, Schiavetti I et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26028","DOI":"10.1002\/ana.26028"},{"key":"5567_CR9","doi-asserted-by":"publisher","first-page":"102908","DOI":"10.1016\/j.msard.2021.102908","volume":"51","author":"A Iovino","year":"2021","unstructured":"Iovino A, Olivieri N, Aruta F, Giaquinto E, Ruggiero L, Spina E, Tozza S, Manganelli F, Iodice R (2021) Alemtuzumab in Covid era. Mult Scler Related Disorders 51:102908. https:\/\/doi.org\/10.1016\/j.msard.2021.102908","journal-title":"Mult Scler Related Disorders"},{"key":"5567_CR10","doi-asserted-by":"crossref","unstructured":"Giovannoni G, Boster AL, Berkovich R et al (2021) Cases of COVID-19 in Alemtuzumab-treated patients with MS: pharmacovigilance report. American Academy of Neurology","DOI":"10.1212\/WNL.96.15_supplement.2059"},{"issue":"7","key":"5567_CR11","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s10072-020-04519-x","volume":"41","author":"G Dalla Costa","year":"2020","unstructured":"Dalla Costa G, Leocani L, Montalban X, Guerrero AI, S\u00f8rensen PS, Magyari M, Dobson RJB, Cummins N, Narayan VA, Hotopf M, Comi G, on behalf of the RADAR-CNS consortium (2020) Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci 41(7):1647\u20131650. https:\/\/doi.org\/10.1007\/s10072-020-04519-x","journal-title":"Neurol Sci"},{"issue":"77(9)","key":"5567_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"1","author":"C Louapre","year":"2020","unstructured":"Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, Deschamps R, Cr\u00e9ange A, Wahab A, Pelletier J, Heinzlef O, Labauge P, Guilloton L, Ahle G, Goudot M, Bigaut K, Laplaud DA, Vukusic S, Lubetzki C et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 1(77(9)):1079\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2581","journal-title":"JAMA Neurol"},{"issue":"3","key":"5567_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","volume":"35","author":"AT Reder","year":"2021","unstructured":"Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C (2021) COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs 35(3):317\u2013330. https:\/\/doi.org\/10.1007\/s40263-021-00804-1","journal-title":"CNS Drugs"},{"key":"5567_CR14","doi-asserted-by":"publisher","unstructured":"Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord.43:102195. doi: https:\/\/doi.org\/10.1016\/j.msard.2020.102195, 43, 102195","DOI":"10.1016\/j.msard.2020.102195"},{"issue":"1","key":"5567_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"H Biying","year":"2021","unstructured":"Biying H, Shaoying H, Lianghong Y (2021) The cytokine storm and. COVID-19- J Med Virol 93(1):250\u2013256. https:\/\/doi.org\/10.1002\/jmv.26232","journal-title":"COVID-19- J Med Virol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05567-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05567-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:27:07Z","timestamp":1725686827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05567-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5567"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05567-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"15 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}